Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 4/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 4/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375105 | 0.84 | KDM1A (0.48) | PARP1OPRL1MAP4K4POLBPDCD1 | |
| SCHEMBL375074 | 0.81 | POLB (0.47) | PARP1OPRL1MAP4K4POLB | |
| SCHEMBL375224 | 0.80 | OPRL1 (0.42) | P2RX7PARP1OPRL1 | |
| SCHEMBL374926 | 0.80 | PARP1 (0.43) | PARP1OPRL1MAP4K4POLBPDCD1 | |
| SCHEMBL2931633 | 0.77 | TEAD1 (0.51) | P2RX7WDR5EPHX1 | |
| SCHEMBL375334 | 0.77 | ALDH1A1 (0.48) | POLBPDCD1CD274 | |
| SCHEMBL20605181 | 0.77 | PARP1 (0.41) | WDR5PARP1OPRL1MAP4K4POLB | |
| SCHEMBL375071 | 0.76 | CARM1 (0.59) | MAP4K4POLB | |
| SCHEMBL17605614 | 0.76 | BCHE (0.54) | OPRL1MAP4K4POLB | |
| SCHEMBL375092 | 0.75 | DUT (0.43) | PARP1OPRL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2409976-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | PTPN7 4533/4885DUSP3 4809/4885P2RX7 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.